

Intarcia Ref. No. INT 004.10
USSN 10/004,118
PATENT

AMENDMENTS TO THE SPECIFICATION

Please replace the paragraph on page 1, line 5, with the following amended paragraph:

Please amend ¶0059, on page 17, lines 21-26 as follows:

[0059] In Figure 2, a graph is presented that shows an increase in the response rate as measured by complete viral clearance in human patients with chronic HCV infection previously untreated with an interferon. Each patient was treated short-term for various periods of time with 15 µg/dose the dosages shown in Figure 2 of omcga-IFN per week, with 7 doses per week for 2 weeks, then 3 doses were given per week on days 1, 3, and 5 of each 7 day week thereafter as shown in Figure 2. The tolerability and safety profile is reasonably well established within 4 weeks after beginning treatment.